Thrombocytopenia in Abbvie Inc Drugs

4 drug(s) with this reaction

2,905 total reports

Overview

Thrombocytopenia has been reported as an adverse reaction across 4 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 2,905 adverse event reports mention thrombocytopenia in connection with Abbvie Inc products.

This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with thrombocytopenia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.

Abbvie Inc Drugs Reporting Thrombocytopenia

The following Abbvie Inc drugs have thrombocytopenia listed in their FDA adverse event reports, sorted by report count:

Other Reactions Reported for Abbvie Inc Drugs

In addition to thrombocytopenia, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:

DRUG INEFFECTIVEPAINARTHRALGIAINJECTION SITE PAINFATIGUERHEUMATOID ARTHRITISHEADACHENAUSEADIARRHOEARASHPSORIASISPAIN IN EXTREMITYJOINT SWELLINGINCORRECT DOSE ADMINISTEREDMALAISEOFF LABEL USENASOPHARYNGITISCROHN^S DISEASEPYREXIADEVICE ISSUE

Frequently Asked Questions

Which Abbvie Inc drugs cause Thrombocytopenia?

4 drug(s) manufactured by Abbvie Inc have thrombocytopenia listed in their FDA adverse event reports: VENETOCLAX, DIVALPROEX SODIUM, RITONAVIR, LOPINAVIR AND RITONAVIR.

How many Thrombocytopenia reports are there for Abbvie Inc drugs?

There are a combined 2,905 reports of thrombocytopenia across 4 Abbvie Inc drug(s) in the FDA adverse event database.

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.